89Bio Inc ETNB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/17/24 EDT
8.63UNCH (UNCH)
Volume
27,261,221
Close
8.63quote price arrow down-0.34 (-3.79%)
Volume
806,351
52 week range
6.57 - 22.93
Loading...
  • Open9.06
  • Day High9.06
  • Day Low8.60
  • Prev Close8.97
  • 52 Week High22.93
  • 52 Week High Date06/13/23
  • 52 Week Low6.57
  • 52 Week Low Date10/23/23

Key Stats

  • Market Cap849.054M
  • Shares Out98.38M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.03
  • YTD % Change-22.74

KEY STATS

  • Open9.06
  • Day High9.06
  • Day Low8.60
  • Prev Close8.97
  • 52 Week High22.93
  • 52 Week High Date06/13/23
  • 52 Week Low6.57
  • 52 Week Low Date10/23/23
  • Market Cap849.054M
  • Shares Out98.38M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.03
  • YTD % Change-22.74

RATIOS/PROFITABILITY

  • EPS (TTM)-2.01
  • P/E (TTM)-4.29
  • Fwd P/E (NTM)-3.85
  • EBITDA (TTM)-179.912M
  • ROE (TTM)-34.51%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)4.89%

EVENTS

  • Earnings Date08/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On 89Bio Inc

 

Profile

MORE
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG)....
Steven Altschuler M.D.
Independent Chairman of the Board of Director
Rohan Palekar
Chief Executive Officer, Director
Ryan Martins
Chief Financial Officer
Quoc Le-Nguyen
Chief Technical Operations Officer and Head of Quality
Address
142 Sansome Street, Second Floor
San Francisco, CA
94104
United States

Top Peers

SYMBOLLASTCHG%CHG
SPRY
ARS Pharmaceuticals Inc
9.03-0.07-0.77%
ALXO
ALX Oncology Holdings Inc
14.21-0.45-3.07%
PLRX
Pliant Therapeutics Inc
15.27-0.34-2.18%
VRDN
Viridian Therapeutics Inc
13.45-1.18-8.07%
TYRA
Tyra Biosciences Inc
18.26-0.84-4.40%